). The kidneys were evaluated for DNA synthesis, cytokine/ chemokine synthesis, cytoskeletal regeneration, and mitosis. Results. Treatment with MSC resulted in reduced inflammatory cytokines synthesized by the kidneys. Mesenchymal stem cell treatment led to a significant increase in the synthesis of adenosine triphosphate and growth factors resulting in normalization of metabolism and the cytoskeleton. Toluidine Blue staining of MSCtreated kidneys demonstrated a significant increase in the number of renal cells undergoing mitosis (26%) compared with EMS perfusion alone. Conclusions. To our knowledge, our work is the first to have demonstrated actual renal regeneration while ischemically damaged human kidneys are perfused ex vivo for 24 hours. The observed regeneration entails: increased synthesis of adenosine triphosphate, a reduced inflammatory response, increased synthesis of growth factors, normalization of the cytoskeleton and mitosis. The ability to regenerate renal tissue ex vivo sufficiently to result in immediate function could revolutionize transplantation by solving the chronic organ shortage.
(Transplantation 2019;103: 307-313) F or the more than 650000 patients with end-stage renal disease in the United States, the pool of deceased donor kidneys has remained essentially stagnant over the past few decades. [1] [2] [3] [4] [5] [6] [7] [8] The deceased donor kidney pool remains largely dependent on traditional donation after brain death (DBD). The DBD donor represents a small fraction of the deaths from traumatic injuries, approximately 4%. 9 The ability to recover warm ischemically (WI) damaged kidneys from uncontrolled deceased by circulatory death (uDCD) donors represents the best near-term chance for expanding the kidney pool. The uDCD kidneys are rarely considered for organ donation because the WI has represented an obstacle. 2, [10] [11] [12] [13] [14] [15] [16] The resulting paradigm is a large discrepancy between the growing demand for kidneys by end-stage renal disease patients, a number doubling each decade, and the pool of deceased kidney donors demonstrating little growth. This is a healthcare issue because although transplantation provides a better quality of life and is more cost-effective, the renal allograft shortage prevents it from becoming a widespread solution. Thus, the dialysis population is expected to reach greater than 2 million patients in the next decade at an aggregate cost of greater than US $1 trillion. 17 We have previously demonstrated the regeneration of severely ischemically damaged renal allografts, using a tissueengineering platform referred to as exsanguinous metabolic support (EMS). Exsanguinous metabolic support is composed of an acellular medium, perfusion system, disposable organ chamber with biosensors to monitor metabolism and a control module. Rather than suppressing metabolism by greater than 96%, as is the case with hypothermic preservation, the restored oxidative metabolism during EMS perfusion is of sufficient magnitude to support new synthesis that provides the basis for cellular reparative processes. 18, 19 We believe the ability to repair ischemic damage ex vivo will provide for a significant expansion of the deceased donor kidney pool by facilitating the use of uDCD donor kidneys that are not used today.
The potential to further accelerate the regeneration of WI damaged human renal allografts was evaluated by introducing a mesenchymal stem cell (MSC) treatment during 24 hours of EMS perfusion. Mesenchymal stem cell were selected for this study because the cells have been shown to be immune evasive and can be transplanted without requisite immunosuppression. Mesenchymal stem cell have also been shown to secrete bioactive molecules such as cytokines/chemokines and growth factors including: granulocyte-colony stimulating factor, leukemia-inhibitory factor, macrophage-colony stimulating factor, PGE2, IL-10, TGFβ, IDO, HO-1, HGF, VEGF, FGF, and IGF-1. [20] [21] [22] [23] [24] [25] The MSC do not directly replace denuded renal epithelial cells. Instead, the cells modulate renal regenerative responses that in turn have been shown to accelerate the recovery phase. [26] [27] [28] This is significant because the cells replacing lost renal epithelium are known to be derived from within the kidney itself. 29 Surviving renal cells dedifferentiate and replicate to restore the epithelium. 30 In contrast, previous work has demonstrated that resident kidney stem cells represent a small population that may be insufficient themselves to therapeutically regenerate a severely damaged human donation after circulatory death kidney. 27 The study hypothesis was that by localizing the MSC to the vascular circulation within damaged human kidneys the repair processes could be potentiated resulting in accelerated recovery of the damaged renal cells. We focused on addressing 2 specific issues:
1. What was the appropriate dose of MSC that could be administrated within the human kidneys for mediation of their paracrine effects without adversely affecting the renal perfusion dynamics? 2. Would this dose of MSC demonstrate a beneficial effect on accelerating renal repair processes?
The evaluations of the repair potential mediated by the MSC included: DNA synthesis, restored cytoskeletal integrity, chemokine/cytokine, and growth factor synthesis and histology. Also, several biomarkers reflecting renal damage were tested. The results of these studies demonstrate therapeutic efficacy when the paracrine effects produced by the circulating MSC are localized to the kidney.
MATERIALS AND METHODS

Paired Human Renal Allograft Model
Kidneys were procured for transplantation according to standard operating procedure and subsequently released to the National Disease Research Interchange once the waiting list had been exhausted. The use of discarded human kidneys exempts studies from ethics board (institutional review board) approval. A dosing study was first conducted that entailed 10 human kidneys to determine the requisite number of MSC to be used in the subsequent studies. The objective was to identify the highest dose of MSC that did not adversely affect the perfusion pressures, vascular flow, or oxygen consumption.
In subsequent studies, an additional 5 pairs of human kidneys were used to determine the potential effect of MSC on the renal regeneration during 24 hours of warm perfusion. The data from the control and test groups was quantified as described below, and the significance was analyzed using the paired Student t test. The known mean WI insult was 30 minutes in 2 pairs of the human kidneys that was calculated as the time from declaration of death after withdrawal of life support until the infusion of cold preservation solution. In 3 additional pairs, the WI time was unknown because the donors were found asystole. The kidney donor characteristics are listed in (Table 1) .
The kidneys were received stored statically in ViaSpan with a mean cold ischemic (CI) time of 29.4 ± 7.4 hours. Therefore, the paired human kidneys tested experienced both WI and CI insults. While a more prolonged WI insult would have been preferred to evaluate renal regeneration, the present study was limited by the current donation criteria for human kidneys procured for transplantation.
EMS Perfusion
The kidneys were weighed, cannulated, and then flushed with warm EMS solution (32°C). and placed on EMS perfusion using 1 L of recirculated perfusate. Restoration of oxidative metabolism and vasodilation were determined by standard criteria of oxygen consumption of greater than 0.1 mL·min , vascular flow greater than 100 mL/min and mean arterial systolic pressures of <60 mm Hg. Once oxidative metabolism and vasodilation were adequately resuscitated, the infusion of MSC into the renal artery of the test kidneys was initiated. One of each of the paired kidneys was used as a control that was warm perfused for the same total time but did not receive treatment with MSC. to a final population of 1 Â 10 8 and immediately used or alternatively stored in the vapor phase of liquid nitrogen until human kidneys became available. In the case of frozen MSC, the cells were thawed and placed in cell culture until the time of use, normally approximately 12 hours during shipment of the human kidneys. Therefore, the MSCs were taken directly from cell culture when infused.
MSCs Labeling
Before infusion, the MSC in cell culture were labeled with PKH26 Red Fluorescent Cell Linker Kit (Sigma Aldrich). Cells were quantified using a Nexcelom Automated T4 Cellometer and adjusted to a working concentration of 2 Â 10 6 MSC/mL. The preselected doses of the infused cell populations were injected intra-arterially. The MSCs were slowly infused to avoid an increase in the perfusion pressures or a decrease in vascular flow. If a negative effect was observed, the infusion was halted until the pressure and flow rate were restored to preinfusion levels. Once the perfusion dynamics became normalized the infusion was continued until the desired targeted dose of MSC was administered and the EMS perfusion continued for an additional 24 hours.
Luminex Cytokine/Chemokine Analysis
Samples of the recirculating perfusate were taken at 30-minute and 24-hour time points during the EMS perfusion of each kidney. The samples were tested using a Multiplex mean arterial pressure (MAP) Human Cytokine/Chemokine Magnetic Bead Panel and analyzed using the Luminex Multiplexing Platform. In addition, the synthesis of growth factors known to be associated with regeneration was also evaluated using the Luminex platform.
Immunohistochemistry
Human kidney samples were flash frozen and sectioned using a Leica 1860UV Cryostat. An indirect immunofluorescence assay was performed with various primary antibodies. The secondary antibodies were conjugated with an Alexa Fluor dye and counterstained with 4′,6-diamidino-2-phenylindole. Images were made using confocal microscopy and analyzed using ImageJ software. Ten representative sections from each of the kidneys were tested and the results analyzed as the mean from respective sections. Proliferating cell nuclear antigen (PCNA) was evaluated as a marker of upregulation in DNA synthesis and zonal occludens-1 (ZO-1) was used to evaluate cytoskeletal repair. Toluidine Blue staining was used to evaluate if there was "actual" renal regeneration by determining if there was any evidence of mitotic figures in the regenerating kidneys after 24 hours of ex vivo perfusion. Mitosis is indicative of renal regeneration by surviving cells recovering synthetic functions sufficiently to undergo cell division to replace lethally injured adjacent cells.
Renal Metabolism
Renal metabolism during the ex vivo perfusion was evaluated by measuring adenosine triphosphate (ATP) synthesis in tissue samples taken from each kidney after 24 hours of EMS warm perfusion. Samples were taken from representative sites from the medulla and cortex and flash frozen in liquid nitrogen. Kidney samples were tested using both a colorimetric adenosine diphosphate/ATP ratio assay kit (Sigma-Aldrich) analyzed on a Victor2 Multiwell Plate reader and then confirmed using high-performance liquid chromatography.
RESULTS
Effect of Introducing MSC in the Ischemically Damaged Human Kidney
The introduction of 25, 50, 75, or 100 Â 10 6 MSC did not adversely affect the renal perfusion pressures (Table 2) . Likewise, at these 4 doses, the vascular flow rate and oxygen consumption were also not adversely affected. Rather, the trend was a reduction in perfusion pressures, an increase in the vascular flow and a rise in the oxygen consumption. In contrast, at a dose of 2 Â 10 8 stem cells, the rise in MAP was associated with reduced vascular flow and a significant reduction in the oxygen consumption. At this dose of MSC, the rise in perfusion pressures remained constant and never normalized ( Table 2 ). This can be attributed to the administration of the high concentration of MSC because the EMS warm perfusion itself is acellular.
Given these results, we selected a dose of 1 Â 10 8 MSC for this study based on the selection of the highest dose of MSC that did not adversely affect the perfusion of the ischemically damaged human kidneys. The rationale for this decision was the hypothesis that the highest dose of MSC would provide the best opportunity to successfully determine the feasibility of MSC-mediated paracrine effects that in turn could accelerate renal regeneration. Because MSCs have been shown not to integrate into parenchyma but rather mediate their regenerative effects via secreted paracrine factors, the hypothesis for a high dose was further supported. into the renal parenchyma or rather simply remained in the circulation. Upon histologic examination of tissue sections, it was determined that no significant migration out of the vasculature into the renal parenchyma had occurred. Collecting the perfusate after the warm perfusion, allowed for the quantification of the MSC in the circulating perfusate because the EMS perfusate itself is acellular. The interpretation of the histologic findings was further supported by the determination that MSC remain predominately in the circulating perfusate. The perfusate was collected at the termination of the 24-hour perfusion, centrifuged, and the MSC were quantified using an automated cell counter. More than 95% of the MSC initially infused into the kidneys were recovered from the recirculated perfusate. These results provide initial evidence that the MSC do not integrate into the renal tissue during 24 hours of ex vivo warm perfusion but rather remain in circulation through the vascular compartment.
ATP Synthesis
When the ATP concentration in the renal tissue was measured (nmol per gram), a statistically significant increase in the concentration of ATP was observed in the MSC-treated kidneys, in both the renal cortex (P = 0.0046) and medulla (P = 0.013) by 24 hours of ex vivo warm perfusion (Figure 1 ). The positive effect of MSC treatment on ATP synthesis was most pronounced in the medulla where the ATP synthesized was more than threefold the concentration over the paired control kidneys that were warm perfused without MSC. Although we do not yet know the mechanism(s) mediated by the MSC treatment that resulted in such increased availability of ATP, nonetheless the increased availability of ATP is known to be associated with increased synthetic functions. Increased synthetic functions are requisite to regeneration of damaged renal tissue.
Renal Synthesis
Using the Luminex platform, we evaluated the synthesis of inflammatory cytokines and found that stem cell treatment led to a reduced proinflammatory state. The results of the known proinflammatory cytokines are listed in (Table 3 ). In each individual inflammatory cytokine that was tested, it was observed that treatment with MSC resulted in a reduced inflammatory status in comparison to the paired control kidneys. The degree of inhibited synthesis varied from cytokine to cytokine. However, the reduced inflammatory state is clinically significant because cytokines such as TNF-α are known to induce expression of adhesion molecules such as ICAM on the surface of vascular endothelial cells lining the vasculature. The upregulated expression of cell adhesion molecules is detrimental to outcomes after reimplantation of an allograft because such upregulation results in enhanced margination and diapedesis of recipient immune cells within the microvasculature of the graft.
In addition, it was found that MSC treatment resulted in increased synthesis of EGF, FGF-2, and TGF-a in the test kidneys compared with the paired control kidneys (Table 3) . Although it was not determined whether the increased concentration of growth factors associated with MSC treatment was produced by the MSC or the renal cells, nonetheless the increased concentration of growth factors was statistically significant (P < 0.05). Also, of note is the known positive effect of growth factors on regenerative pathways after ischemic injury. Growth factors mediate their positive effect by acting as trophic factors and functioning as second messengers. The growth factors are also known to mediate increases in metabolic rate, are mitogenic for damaged renal tubules, promote restoration of cytoskeletal integrity, and help to restore cell surface polarity.
Cytoskeletal Repair
ZO-1 is a tight junctional protein that was used to evaluate repair to the cytoskeleton. Zonal occludens-1 is normally expressed exclusively at the plasma membrane localized to the point of cell-to-cell contact. After an ischemic injury that damages the cytoskeleton, ZO-1 diffuses from the cell membrane becoming dispersed within the cytoplasm. The dispersion of ZO-1 into the cytoplasm can therefore be used as a marker of cytoskeletal injury, and the restoration of tight FIGURE 1. Pathways of Regeneration (ATP Synthesis). ATP concentration was tested in human renal biopsies after 24 hours of exsanguinous metabolic support (EMS). In test kidneys, mesenchymal stem cells (MSC) were administered intra-arterially and compared to EMS treatment alone in the paired kidney. MSC-treated human kidneys showed a significant increase in ATP concentration compared to controls in samples taken from the cortex and medulla, *P < 0.05. (n = 5 pairs). cellular junctions can be interpreted as a reparative process to the cytoskeleton. Using Image J software to objectively quantify differences in fluorescence, a 4.81% increase in restoration of cytoskeletal integrity was observed in MSC-treated kidneys. The control kidneys displayed significant normalization of the cytoskeletal integrity supported by the warm perfusion alone at 24 hours. The test kidneys that were treated with MSC only marginally increased the rate of normalization after 24 hours of warm perfusion, 44.18 ± 8.67% compared with 48.99 ± 5.95% of total fluorescence where a decrease represents reduction in cytoplasmic staining. Although this marginal increase was not statistically significant, the phenomenon was observed in all the test kidneys demonstrating the reproducibility of the reparative process.
PCNA
We used PCNA as a marker of upregulation in DNA synthesis. Using Image J, we found the mean number of PCNA-positive nuclei in the control group kidneys was 194.8 ± 45.92 per 413 nuclei (47.1%). In MSC-treated kidneys, we found an average of 215.3 ± 24.63 per 413 nuclei (52.1%) (Figure 2 ). Using a paired Student t test, it was determined that there was a significant difference between the 2 groups (P = 0.049). In previous studies, it was observed that PCNA upregulation during the EMS perfusion occurred within 6 hours, far sooner than the 24 hours threshold observed in vivo after an acute kidney injury. 31 By testing for PCNA at 24 hours, a more pronounced difference may have been underestimated because of earlier upregulation.
Mitosis
During the evaluation of the hematoxylin and eosin-stained kidney sections, cells in various stages of mitosis were observed. The tissue sections were then further studied using toluidine blue staining. The positive stained cells were counted per field with a total of 40 separate fields. Although renal cells with mitotic figures were observed in all warm perfused human kidneys, the kidneys that were MSC treated demonstrated an increased number of renal cells with mitotic figures. In the control kidneys, the mean number of cells positive for mitotic figures was 47.7 ± 4.4 per 168 cells (28%), whereas in the MSC-treated kidneys, the cells undergoing mitosis increased to 60.2 ± 3.84 per 168 cells (35.9%) . The results demonstrated a 26% increased incidence of mitosis associated with the MSC treatment (P < 0.05) (Figure 3) . In a normal kidney, the number of renal cells undergoing division is quite low, with normal cell turnover occurring in terms of years. 32 FIGURE 2. Pathways of regeneration (DNA synthesis). Human renal biopsies were taken after 24 hours of exsanguinous metabolic support (EMS) with or without the addition of 1 Â 10 8 amesenchymal stem cell (MSC). Tissue samples were fixed in 4% formaldehyde, processed, and embedded in paraffin wax for sectioning. An indirect immunofluorescent assay was performed using a mouse anti-PCNA antibody (ABCAM) and Goat Anti-Mouse Alexa Fluor 488 secondary. A, PCNA expression after 24H of EMS perfusion. B, MSC-treated human kidneys resulted in a significant increase in PCNA-positive nuclei in the paired test kidneys (P < 0.049) (n = 5 pairs). 
Potential of Long-term EMS Perfusion
To accomplish a more complete regeneration of WI damaged human renal allografts; a longer reparative process during ex vivo warm perfusion will be needed. To be assured that a longer period of EMS kidney perfusion can be successfully achieved, we conducted 2 experiments involving 2 additional human renal allografts that were perfused for 3 days. The kidneys were from DBD donors and therefore, not WI damaged. Because the kidneys were not WI damaged, it was possible to assess whether a prolonged period of ex vivo warm perfusion would mediate damage. Throughout the 3 days of ex vivo perfusion of the human kidneys, the perfusion pressures remained stable (MAP <60 mm Hg), vascular flow remained greater than 170 mL/min, oxygen consumption was greater than 0.13 mL·min . At the end of the 3-day perfusion, the kidneys were flush fixed and placed in paraffin blocks after which they were sectioned. The histologic evaluations involved samples from 5 representative sites within each kidney that were hematoxylin and eosin stained. The findings demonstrated normal vessels and glomeruli. The tubule epithelium was also normal with the occasional, mild cystic dilation of tubules. Because the parameters of the perfusion were constant throughout the 72 hours of testing and histologic evaluations did not find evidence of damage, we believe that additional days of perfusion is feasible. This observation confirms previous work performed by our group that demonstrated the feasibility of warm perfusing human renal allografts for several days. 33 A longer period of ex vivo warm perfusion would provide an increased opportunity for renal regeneration.
DISCUSSION
To our knowledge, this is the first report of active cellular regeneration in ischemically damaged human kidneys resulting in renal cells undergoing mitosis during 24 hours of ex vivo perfusion. In previously published work, ex vivo warm perfusion was found to ameliorate reperfusion injury when the kidneys were reimplanted directly from EMS perfusion. 19 Cellular repair during ex vivo warm perfusion is obviously distinct from the inflammatory and coagulation responses that occur in vivo with normal physiologic responses to injury. In contrast, the repair observed during EMS perfusion is more analogous to the cellular recovery that occurs after resuscitation of oxidative metabolism in cells placed in tissue culture. We have previously reported that a period of ex vivo warm perfusion in an exsanguinous environment results in resuscitation of oxidative metabolism, reestablishment of cell volume regulation and recovery of the cytoskeletal integrity after a prelethal warm ischemic injury. 18, 19 The results of this earlier work demonstrated that resuscitation of metabolism during ex vivo warm perfusion in an acellular environment was of sufficient magnitude to support de novo protein synthesis that is the basis of cellular reparative processes. However, although this work addressed cell repair after a prelethal injury, a period of delayed graft function (DGF) still occurred. The DGF represents the renal cells that were lethally injured and could not be repaired during warm perfusion but rather required that surviving renal cells regenerated sufficiently to undergo mitosis to replace the lethally injured cells. A hallmark of DGF is acute tubular necrosis and if the ischemic insult is severe, there is a well-recognized increased risk of primary nonfunction. Therefore, DGF represents the time requisite to regenerating the lethally injured renal cells and restoring normal renal function. Regeneration is mediated by nonlethally injured (surviving) tubular epithelial cells that dedifferentiate and proliferate to replace the lethally (irreversibly) injured tubular epithelial cells to restore renal integrity. The resulting proliferative response is rapid, involving numerous remaining tubular cells. 27, 34 The mitogenic response is driven by paracrine factors at sites of severe injury and supports the findings of MSC treatment in this study. 35 The mitogenic potential of proximal tubule cells is the reason for the therapeutic use of growth factors to accelerate recovery from acute renal failure. 36 Similarly, an inflammatory response contributes to the injury cascade. The transmigration of immune cells into the transplant is a well-known mechanism that is associated with reperfusion injury and the development of DGF. 37, 38 The diapedesis is mediated by the chemokines released from injured renal cells, such as macrophage chemoattractant protein. 36, 39 Injured proximal tubule cells are known to secrete proinflammatory cytokines such as TNF-α, and IL-6. 39 In this study, treatment with MSC led to a reduced inflammatory state. Our goal was to determine whether a stem cell treatment during 24 hours of ex vivo warm perfusion could be useful in accelerating the replacement of lethally injured renal cells after ischemic injury that leads to acute tubular necrosis. Mesenchymal stem cell treatment of ischemically damaged human kidneys resulted in a significant increase in ATP concentration compared to the paired untreated control kidneys. Of note, ATP was significantly increased in the medulla where the S3 segment tubules known to be particularly sensitive to WI are located.
With ATP depletion, disruption of the cytoskeleton occurs leading to further damage to mitochondrial function that in turn interferes with production of ATP. 40 ATP depletion, particularly in the S3 segment of the proximal tubule, leads to the disruption of cell-cell junctional complexes that maintain the cytoskeletal integrity. 41, 42 The increased availability of ATP correlated with increased synthetic functions that are dependent upon cellular energetics. The increased synthetic functions associated with MSC treatment included significantly increased synthesis of the growth factors involved with renal regeneration.
The difference in the repair of the cytoskeletal integrity was not significant between the test and control human kidneys at 24 hours of ex vivo warm perfusion. This observation was not surprising given our previous work where significant repair to the cytoskeleton of the renal cells with a prelethal insult was observed by 24 hours of warm perfusion. In lethally injured renal cells, no cellular repair can be expected because the cells would need to be replaced rather than repaired. The observation of mitosis during 24 hours of ex vivo warm perfusion provides irrefutable evidence of actual renal regeneration in damaged human kidneys. A significant increase in the number of renal cells undergoing mitosis was observed in association with MSC treatment. Publications pertaining to warm perfusion of liver, lung and kidney allografts have previously used terminology such as "conditioning, reanimation, recovery, repair, etc." to define the benefit of warm perfusion. However, actual repair on a cellular basis via mitosis has not been previously demonstrated.
We now wish to move forward with additional studies where we will extend the period of warm perfusion to several days to attempt a more complete repair of tubule damage. The irrefutable evidence of actual renal regeneration resulting in normal, life-sustaining function awaits our future planned preclinical kidney transplantation studies. The ability to regenerate damaged kidney allografts ex vivo after a severe ischemic insult sufficiently to result in immediate function upon reimplantation will be the goal of future studies. If successful, this approach could open the way to significantly expanding donor criteria by procuring kidney allografts from the uDCD.
